These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gender differences in the prevalence and severity of bone disease in thalassaemia. Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, Skordis N. Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164 [Abstract] [Full Text] [Related]
3. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559 [Abstract] [Full Text] [Related]
8. Treatment for osteoporosis in people with ß-thalassaemia. Bhardwaj A, Swe KM, Sinha NK, Osunkwo I. Cochrane Database Syst Rev; 2016 Mar 10; 3():CD010429. PubMed ID: 26964506 [Abstract] [Full Text] [Related]
12. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]. Cheng ZQ, Yin W, Fan JY, Ma TJ. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun 10; 24(3):306-9. PubMed ID: 12905641 [Abstract] [Full Text] [Related]
16. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy. Legroux-Gerot I, Vignau J, Collier F, Cortet B. Calcif Tissue Int; 2008 Nov 10; 83(5):315-23. PubMed ID: 18836675 [Abstract] [Full Text] [Related]